| Name | Title | Contact Details |
|---|
The PAISBOA Health Benefit Trust (HBT) is a consortium of independent schools, colleges, and universities within the state of Pennsylvania. The sole focus of the HBT is to provide high-quality health plans at affordable rates. Members enjoy savings, stability, and innovative programs through scale and collaboration. The PAISBOA HBT is a self-funded entity, organized as a Multiple Employer Welfare Association (MEWA). While the HBT was established by and exists for the benefit of its member institutions, it is governed by a dedicated Board of Trustees who are elected by the members to ensure that the needs of all of the enrolled participants are represented.
The Ken Ganley Automotive Group is the fastest growing dealership group in Northeast Ohio and beyond! We currently rank #1 in Ohio and #14 in the country. Our group is a collection of best-in-class dealerships that offer a wide array of quality new and used car models in convenient locations. At the Ken Ganley Auto Group, we believe that our people are our most important assets, along with our culture of leadership, integrity, customer focus and teamwork. Our people are the foundation of our brand, and our success is dependent on preserving our reputation of respect and quality. We are a company that believes in our core values and upholding them through great people, high standards and best practices. The core values of our organization are what shape every action we take and every decision that is made. We are defined by our integrity. We believe in doing what is right for our fellow team members, our customers and our corporate partners. We are responsive, professional, and handle every experience honestly and with class. Together, we have created an image that has resulted in a positive public perception. The image of a leader. Our customers are our #1 priority. We treat them like family, working hard to exceed their expectations. We are committed to continuing our tradition of success, performance and quality customer service. Our team members are entrusted to make sure each and every customer feels valued and listened to. When a customer enters our dealerships, they know they will have a dependable, quality experience every time. Thanks for visiting our page and well see you soon in the showrooms!
Ayesa is a global provider of technology and engineering services with more than 11500 employees in twenty-three countries across Europe, Latin America, Africa and Asia. The company develops and implements digital solutions for the private and public sector and uses the latest technology to provide cutting-edge infrastructure design and supervision services. To do this, it has certified experts covering more than 70 different disciplines in utilities and energy; the public sector; banking and insurance; water and the environment, transportation; aeronautics and defence; and construction. As a company that is driven by people and innovation, its business approach is underpinned by talent.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.